SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
16815317
Source:
http://linkedlifedata.com/resource/pubmed/id/16815317
Search
Subject
(
60
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0022671
,
umls-concept:C0072980
,
umls-concept:C0205360
,
umls-concept:C0376387
,
umls-concept:C0442027
,
umls-concept:C0449297
,
umls-concept:C1515568
,
umls-concept:C1706122
pubmed:issue
1
pubmed:dateCreated
2006-7-3
pubmed:abstractText
The low and highly variable oral bioavailability of the immunosuppressant sirolimus is thought to result partly from genetic polymorphism of the CYP3A5 gene.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/0372741
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A5 protein, human
,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A
,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System
,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid
,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus
,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0009-9236
pubmed:author
pubmed-author:DjebliNassimN
,
pubmed-author:HoizeyGuillaumeG
,
pubmed-author:Le MeurYannickY
,
pubmed-author:MarquetPierreP
,
pubmed-author:RérolleJean PhilippeJP
,
pubmed-author:SzelagJean-ChristopheJC
,
pubmed-author:ToupanceOlivierO
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-60
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:16815317-Adult
,
pubmed-meshheading:16815317-Area Under Curve
,
pubmed-meshheading:16815317-Biological Availability
,
pubmed-meshheading:16815317-Cytochrome P-450 CYP3A
,
pubmed-meshheading:16815317-Cytochrome P-450 Enzyme System
,
pubmed-meshheading:16815317-Female
,
pubmed-meshheading:16815317-Genotype
,
pubmed-meshheading:16815317-Humans
,
pubmed-meshheading:16815317-Immunosuppressive Agents
,
pubmed-meshheading:16815317-Kidney Transplantation
,
pubmed-meshheading:16815317-Male
,
pubmed-meshheading:16815317-Metabolic Clearance Rate
,
pubmed-meshheading:16815317-Middle Aged
,
pubmed-meshheading:16815317-Mycophenolic Acid
,
pubmed-meshheading:16815317-Pharmacogenetics
,
pubmed-meshheading:16815317-Polymorphism, Single Nucleotide
,
pubmed-meshheading:16815317-Sirolimus
pubmed:year
2006
pubmed:articleTitle
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
pubmed:affiliation
Service de Néphrologie and Service de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire, Limoges, France. Yann.Lemeur@chu-limoges.fr
pubmed:publicationType
Journal Article
,
Research Support, Non-U.S. Gov't